Zilovertamab vedotin
Phase 1/2Recruiting 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
B-cell Acute Lymphoblastic Leukemia
Conditions
B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma
Trial Timeline
Aug 16, 2024 → Mar 31, 2029
NCT ID
NCT06395103About Zilovertamab vedotin
Zilovertamab vedotin is a phase 1/2 stage product being developed by Merck for B-cell Acute Lymphoblastic Leukemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06395103. Target conditions include B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06395103 | Phase 1/2 | Recruiting |
| NCT05144841 | Phase 2 | Active |
| NCT04504916 | Phase 2 | Terminated |
| NCT03833180 | Phase 1 | Completed |
Competing Products
20 competing products in B-cell Acute Lymphoblastic Leukemia